ApexOnco Front Page Recent articles 1 August 2025 FDA red and green lights: July 2025 Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks. 31 July 2025 Instilling confidence in ImmuneOnco's bispecific The first data are dribbled out, but cross-trial comparisons look uninspiring. 24 May 2024 Verastem spoils its ASCO bounce An initial winner of the ASCO abstract reveal, Verastem drops a bombshell. 24 May 2024 ASCO 2024 abstract movers – Merus convinces, at first Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers. 23 May 2024 ASCO 2024 preview – toxicity looms large for J&J Four deaths cast doubt on J&J’s multi-pronged KLK2 push. 23 May 2024 ASCO 2024 preview – jury still out on AbbVie's cancer push SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs. 23 May 2024 ASCO 2024 preview – two strikes against USP1 Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive. 23 May 2024 ASCO 2024 preview – new Car-T target shows liver cancer promise Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank. Load More Recent Quick take Most Popular